Dow Records Losses For Second Straight Week But Investor Optimism Improves

The CNN Money Fear and Greed index showed some improvement in overall market sentiment. US stocks closed lower on Friday amid rising concerns over recession as the Federal Reserve continues increasing interest rates. The Fed raised rates by 50 bps at its recent meeting.

The CNN Money Fear and Greed index showed some improvement in overall market sentiment.

US stocks closed lower on Friday amid rising concerns over recession as the Federal Reserve continues increasing interest rates. The Fed raised rates by 50 bps at its recent meeting.

Wall Street recorded losses for the second straight week, with the S&P 500 dropping over 2% last week.

The Dow closed lower by around 282 points to 32,920.46 on Friday. The S&P 500 fell 1.11% to 3,852.36, while the Nasdaq Composite fell 0.97% to settle at 10,705.41 in the previous session.

Steelcase Inc. (NYSE:SCS) and HEICO Corporation (NYSE:HEI) are set to report quarterly earnings today.

At a current reading of 55.0, the index remained in the “Neutral” zone, compared to a previous reading of 45.0.

What is CNN Business Fear & Greed Index?

The Fear & Greed Index is a measure of the current market sentiment. It is based on the premise that higher fear exerts pressure on stock prices, while higher greed has the opposite effect. The index is calculated based on seven equal-weighted indicators. The index ranges from 0 to 100, where 0 represents maximum fear and 100 signals maximum greediness.

Check this out: This Roblox Options Trader Sees Stock Tumbling By This Double-Digit Figure By January Expiration

Total
0
Shares
Related Posts
Read More

2U, Inc. Announces Leadership Transition; Paul Lalljie Appointed CEO, Joins Board Of Directors; Matthew Norden Appointed CFO; Christopher “Chip” Paucek Departing As CEO And Member Of The Board Of Directors, Becoming Special Advisor

2U, Inc. (NASDAQ:TWOU), a leading online education platform company, today announced a change of leadership to spearhead the next stage of its evolution as it focuses on improving operational efficiency and delivering

TWOU

Read More

Reported Nov 9, Neurocrine Biosciences Provides Development Pipeline Update; Failed To Demonstrate Meaningful Reduction In Seizure Frequency; Failed to Meet Its Primary Endpoint In Patients With Anhedonia In Major Depressive Disorder

Phase 2 Proof-of-Concept Study of NBI-921352 in Patients with Focal Onset Seizures Failed to Demonstrate Meaningful Reduction in Seizure FrequencyPhase 2 Proof-of-Concept Study of NBI-1065846 in Patients with Anhedonia

NBIX